Finding rapid, reversible downregulation of human UDP-glucuronosyltransferases (UGT) in LS180 cells following curcumin-treatment led to the discovery that
Mammalian endoplasmic reticulum (ER)-bound UDP-glucuronosyltransferase (UGT) isozymes carry out the broad and critical function of detoxifying endogenous and exogenous lipophilic phenols that include toxic metabolites, dietary constituents, environmental carcinogens and, inadvertently, therapeutic agents. UGT isozymes inactivate a vast number of structurally diverse chemicals by attaching glucuronic acid to generate water-soluble products with high excretability.
Because lipid-solubility of chemicals taken into the body largely determines membrane permeability governing their absorption, distribution, and excretion, glucuronidation is the primary cellular process that protects against such chemicals (1) , which are encountered on a regular basis due to their ubiquitous presence in dietary plants, pyrolysates of wood and petroleum products, distributions related to consumer and agricultural activities, and therapeutic agents. Critical endogenous substrates include bilirubin, steroids and their metabolites, bile acids, retinoic acids, thyroid hormones and others (1) . In the case of defective UGT -/-, lipophiles accumulate in tissues leading to deleterious effects. Defective bilirubinconjugating UGT1A1 (2) in Crigler-Najjar (UGT1 -/-) children causes elevated bilirubin levels that deposit in the central nervous system leading to kernicterus. Importantly, ingested dietary and environmental polyphenols are sometimes general toxins and genotoxins that can initiate cancer (3) . To a detriment, glucuronidation converts medicinal chemicals, which leads to premature termination of therapeutic activity. Hence, it is essential to understand the mechanism(s) controlling this vital process.
As individual recombinant UGTs are shown to have broad substrate activity toward aromatic-like chemicals (4), the 17 known viable members of the human superfamily of UGTs, distributed in families A, B and C, collectively convert an unlimited number of chemicals. Because the ER-bound UGT isozymes have proven difficult to purify for tertiary structural analyses, the critical properties and mechanism(s) controlling catalytic activity are not understood. Whereas it has been demonstrated that UGT catalysis requires ongoing regulated phosphorylation (5) (6) (7) and that substrate selection may relate to phospho-group participation (7), it is critical to understand factors controlling the regulated phosphorylation.
Moreover, high concentrations of certain oxidizable flavonoids and polyphenols found in the diet are or become inhibitors of critical enzymes (8, 9 ), which we have now shown to include UGTs (5) (6) (7) . By contrast, low levels of such chemicals often serve as antioxidants and chemopreventive agents (10) , demonstrating the importance of chemical homeostasis. Here we demonstrate the relevant kinases and mechanism(s) involved in the regulation of ongoing phosphorylation of UGTs mediated by PKC signal transduction, which accounts for UGTs vulnerability to high concentrations of antioxidants.
EXPERIMENTAL PROCEDURES
Materials -Human LS180 colon and COS-1 cells were from ATCC (Manassas, VA). Tissue culture medium was from Cellgro, (Rockville, MD), and serum was from Intergen (Purchase, NY). UGT substrates, curcumin, calphostin-C, calyculin-A, 1,2 dihexanoyl-sn-glycerol (DAG), phorbol 12-myristate 13-acetate (PMA), and phosphatidyl serine (PS), kinase inhibitors, the MTT kit, catalase, and herbimycin-A were from either Sigma (St. Louis, MO) or Calbiochem (San Diego, CA); [
14 C]-UDP-glucuronic acid was from New England-Perkin-Elmer. PKCε translocation-activator and inhibitor peptides were from Calbiochem or Dr. D. Mochly-Rosen (Stanford University). Monoclonal anti-β-COP (ε-RACK) was from Sigma; anti-His was from Amersham-Biosciences; and antibodies toward phosphoserine and protein kinase C isozymes were from Upstate Biotechnology (Lake Placid, NY) or Calbiochem. Donkey secondary antibodies conjugated with FITC or TRITC were from Jackson Immunoresearch Laboratories (West Grove, PA). The immunogenic phosphogroup in PKCε is 729 (Upstate, cat. # 06-821). PKCε-specific siRNA (ON TARGET plus SMART Pool, Human PRKCE) and its nontargeting siRNA control were from Dharmacon (Chicago, IL). TNT R T7 Coupled Wheat Germ extract system was from Promega (Madison, WI). Rabbit anti-calnexin and rabbit anti-calreticulin were from Stressgen Biotechnologies (Victoria, Canada). The rabbit UGT1A-common-end (CE) (11) and goat UGT-1168 antibodies have been described (12) .
pSVL-based constructs containing UGT1A1 (2), UGT1A3 (6), UGT1A4 (2), UGT1A6 (13), UGT1A7 through UGT1A10 (4), UGT2B7 (12) or UGT1B15 (14) were cloned or custom synthesized.
Growth and Transfection of Cells -LS180 colon and COS-1 cells were grown in DMEM with 10 and 4 % fetal calf serum, respectively, and exposed to reagents solubilized in fresh dimethyl sulfoxide diluted to < 0.5%. Cell viability was checked with a MTT kit after treatment with curcumin, calphostin-C, herbimycin-A and other inhibitors as described in the text. Ten different pSVL-based UGT-cDNAs were transfected into COS-1 cells for specific protein expression as previously described (2). Also, His-Tag affinity ligand from the pcDNA3.1 vector (Invitrogen, Carlsbad, CA) was fused in-frame at the 3΄ end of the cDNA in pSVL-UGT1A7 and pSVL-UGT1A10.
Glucuronidation Assay -Cellular extracts were analyzed for in-vitro glucuronidation with abolition of UGT latency as previously described (15, 16) . Common donor substrate, UDP-[ 14 C]glucuronic acid (1.4 mM, 1.4 μCi/μmol), was used in all reactions with unlabeled acceptor substrate. Incubations used 150 or 300 μg of cellular protein at pH 6.4 or 7.6 for 2 hr at 37°C (4), and glucuronides were separated by thin layer chromatography.
Product was quantified as previously described (15) using appropriate controls. Protein content was estimated using the BCA kit (Peirce, Rockford, IL). Product represents pmol glucuronide/mg prot/per unit time.
Western Blot Analysis of UGTs and Protein
Kinases in Cells -Relative amounts of UGT in transfected-COS-1 and LS180 cells were established by Western blot as previously established (5, 11) . Twenty-five μg of cellular homogenate were solubilized in SDS-sample buffer, applied to polyacrylamide (PAGE)-SDS gel and subjected to electrophoresis. Following protein electrotransblotting onto nitrocellulose membrane, regular blots were processed as previously described (11) for exposure to x-ray films. Membranes used with antibodies to target phospho-groups were blocked and processed as described (7) . Blots were exposed to antibody specific for the protein of βII-, δ-, γ, and ζ-PKC (not shown), of α-and ε-PKC, of MAP44/42 or to antibody specific for the phosphate group in PKCε (Ser-729), PKCα (Ser-657) or MAP44/42 according to supplier's instructions. Membranes were exposed to appropriate secondary antibody-HRP conjugate and visualized as described for anti-UGT.
In-situ Labeling of UGT and PKCε with [
33 P] Orthophosphate -To determine whether UGTs undergo phosphorylation, LS180 cells were grown to nearly 100 % confluency and processed as previously described (7, 17) . All conditioned cells were exposed to [ 33 P] orthophosphate and to curcumin for 1 to 8 hr to allow maximum inhibition and recovery or to calphostin-C for the final one hr.
Cells were harvested and solubilized; equal protein was allowed to immunocomplex with anti-UGT-CE, washed (12) and subjected to electrophoresis in a SDS-7.5 % PAGE system. Similarly, solubilized cell extracts were immunocomplexed with anti-PKCε protein backbone, washed and resolved by SDS-PAGE. Finally, the UGT-or PKCε-containing gel was fixed, dried, and scanned for quantitation as described for [ 14 C] -glucuronides (15) . Both gels were exposed to x-ray film. Co-localization Studies-To determine whether UGT1A7His and phospho-PKCε co-localize, COS-1 cells, grown on Lab-Tek slides (Nalgene, Frederick, MD), were transfected (7) with pUGT1A7His. Cells were processed for immunofluorescence (7) by exposure to primary antibodies: rabbit anti-phospho(Ser729)PKCε and mouse anti-His-Tag (Amersham, Piscataway, NJ). Phospho-PKCε and 1A7His were visualized with donkey anti-rabbit-FITC conjugate (Jackson Laboratory) and donkey anti-mouse-TRITC conjugate (West Grove, PA), respectively. Their images were assembled by computer using a photometric Zeiss microscope (Germany). For UGT1A10 and PKCα co-localization, rabbit anti-UGT-CE (4, 5, 11) 33 P] ATP (2.2 μCi/pmol) and other kinasing reactants (Upstate) were combined in 60 μl and allowed to react for 20 min at 30 ºC according to the manufacturer's protocol. Aliquots (10 μl) of the reaction mixture were added to P81 cellulose membrane, washed with 0.75 % phosphoric acid, acetone, air dried, and counted using a liquid scintillation system according to Promega's protocol. Also, the 250-μl reaction-system was solubilized with equal volume of 2x-Kinexus buffer, centrifuged at 10,000 x g for 20 min, supernatant was added to Ni+-charged resin (Sigma) and the purification strategy followed the source's protocol. Duplicate 4 →15% gradient SDS-PAGE systems were loaded with processed samples and electrophoresed; one gel was dried and exposed to x-ray film for development, and the duplicate gel was transblotted onto a nitrocellulose membrane and analyzed by Western blot as previously described using antiHis and anti-UGT-CE as already described.
Treatment of LS180 Cells with Catalase and
Hydrogen Peroxide -To test effects of reactive oxygen species on constitutive UGT activity, untreated LS180 cells were exposed to different concentrations of catalase or herbimycin-A. Also, cells were treated with different concentrations of H 2 0 2 or combinations of H 2 0 2 and catalase or herbimycin-A (20-23), or of H 2 0 2 with curcumin or calphostin-C. Cellular extracts were tested for glucuronidation of eugenol and capsaicin (4) .
RESULTS

Inhibition of UGTs Expressed in COS-1 and LS180 Cells by Curcumin or Calphostin-C
Treatment -Our attempts to uncover special UGT properties associated with function began with a screen to discover new regulatory molecules among UGT substrates. While comparing in-cellulo treatment of two members, UGT1A7 and 1A10, of human UGT1A family that have similar propterties, 1A7 was dramatically downregulated by 200 μM curcumin, but 1A10 showed minor inhibition ( Figure 1A ). With appropriate concentrations, there was rapid inhibition with recovery for all UGTs tested, re-exposure to curcumin caused the cycle to repeat for the three times tested (data not shown), suggesting the involvement of signaling events (24-28). As the substrate, curcumin, has been associated with antioxidant-, antiinflammtory-, anticarcinogenic-effects in cells (24-26) and with inhibition of kinases (28), we tested other kinase inhibitors and found treatment with calphostin-C, a PKC-specific inhibitor (29) , also rapidly downregulated UGT, but without recovery ( Figure 1A ). Interestingly, curcumin behaved as a typical substrate under invitro conditions. Comparing equal protein amounts of UGT1A7 and 1A10 and increasing curcumin concentrations, saturation kinetics were observed with both isozymes ( Figure 1B ), except 1A10 activity was approximately twice that of 1A7.
Effects of curcumin-treatment of ten independently expressed UGTs --1A1, 1A3, 1A4, 1A6, 1A7 through 1A10, 2B7 and 2B15--in COS-1 cells show each was inhibited without affecting specific protein (Figure 2) , and the inhibitory level of curcumin was isozymedependent ( Figure 2 ). Analysis of concentrationdependency of curcumin and calphostin-C for two isozymes with contrasting characteristics (4, 7) showed UGT1A7 was among the most sensitive to the reagents, and UGT1A10 was the most resistant ( Figure 1S ). The concentration profiles for the 8 other isozymes are not shown.
Immunoprecipitates of UGT1A7 and 1A10 with anti-UGT-CE again (4, 6, 7, 11) showed there had been no effect on specific protein level, while immunoreactivity of anti-phospho-serine demonstrated (7) curcumin and calphostin-C caused concentration-dependent loss of phosphoserine in 1A7 and 1A10 ( Figure 1S , top) with the former showing 2-fold greater sensitivity than the latter.
These observations, including concentration-dependent inhibition of the 10 recombinant UGTs, led us to conclude all UGT isozymes likely require phosphorylation that involves PKC isozymes. Moreover, predicted PKC phosphorylation sites by computer analysis have been identified in each of the 10 UGTs analyzed (5).
Antibodies toward Different Kinases Distinguished the Effect of Curcumin on UGTs -
Since several UGT isozymes are constitutively present in LS180 cells, we attempted to determine effect(s) of curcumin and calphostin-C on PKCs and UGT activities and their phosphorylation status. Because calphostin-C is a PKC-specific inhibitor, we initially examined its effect on LS180 cells by Western blot with antibodies against the protein backbone for α-, βII-, δ-, ε-, γ-, and ζ-PKC. After observing a change in profile for only PKCε following 50-μM curcumin treatment, we examined blots with anti-phosphoserine-729-PKCε and found the phospho-pattern (corrected with phospho-PKC/backbone PKC ratios) closely paralleled that for UGT-activity (normalized with specific UGT levels shown in Figure 3A Figure  3A , panel 4). Antibody to phospho-44 gave a progressive decrease in reactivity, and that toward phospho-42 gave a progressive increase. While there was no detectable MAP 44/42 kinase involvement, PD98059 (MEK inhibitor) (10 µM) caused a modest 30% inhibition of UGT in 2 hr. In addition, the calcium-channel blockers, nifedipine (500 nM, 20 % inhibition) and TMB-8 (2.5 µM, 15 % inhibition), or calmodulin antagonist, calmidazolium (1.0 µM, 16% inhibition), had little effect on UGT (data not shown). The dramatic loss of phosphate-729 in PKCε suggested curcumin, most likely, affected phosphorylation. Parallel loss of UGT activity and phospho-PKCε suggested this isozyme carried out a phophorylation event(s) critical for UGT(s) activity.
Furthermore, inhibition of at least 6 different substrate activities tested with extracts of curcumin-and calphostin-C-treated LS180 cells and of similar extracts of COS-1 cells independently transfected with 8 UGT1-encoded cDNAs and 2 UGT2B-encoded cDNAs (UGT2B7 and UGT2B15) ( Figure  2 ) indicates phosphorylation is likely required for all UGTs.
Fate of Curcumin During Reversal of Inhibition -
In order to understand the reversal of inhibition, we determined the fate of 50 μM curcumin in LS180 cells.
Combined results after the independent analysis of culture medium and of cell extract by HPLC (30) showed that at 15 min there was 98.5 % free curcumin and 1.5 % curcumin-glucuronides; between 1 and 24 hr free curcumin progressively decreased, and its glucuronides progressively increased in Table 1 . A marked decrease in curcumin levels occurred between 2 and 3 hr after treatment, which also compares to a significant increase in UGT activity ( Figure 3A, panel 4) . Hence, recovery appeared to depend upon reduction of free curcumin to noninhibitory levels by residual but progressively increasing UGT activity that simultaneously relieved PKCε inhibition. Importantly, UGT1A7 and 1A10 transfected cells, treated with 50μM curcumin or 250nM calphostin-C for 24 hr and up to 400 μM curcumin or 1.0 μM calphostin-C for 3 hr, did not show cell loss or toxicity by the MTT assay, which was similar to previous reports (21, 31, 32) . While results provide evidence kinase-dependent cycling event(s) are required for UGT activity, reversal of curcumin inhibition is likely due to its glucuronidation by low UGT activity remaining that progressively increases with time.
Effect of Other PKC Inhibitors on UGT ActivityAlso, treatment of LS180 cells with other PKC inhibitors at different concentrations decreased UGT activity (data not shown) within 15 to 120 min as follows: bisindolemaleimide (BIM) (250 nM) by 40 %, chelerythrine (2 μM) by 20 %, Gö-6976 (1.0 μM) by 20 % and Ro-320432 (250 nM) by 30 %. Ten μM BIM, chelerythrine or Ro-320432 caused between 50 and 62 % inhibition as seen earlier (7). Moreover, two PI-3 kinase inhibitors, LY294002 (500 nM) and Wortmanin (10 µM), caused 30-40 % inhibition after 2 hr. Also, we observed that UGT in LS180 cells, treated with 25 μg/mL cyloheximide, showed a modest 25 % decrease in activity after 144 hr, indicating a substantially long half-life and that loss of activity is unrelated to specific protein degradation (data not shown). Figure 3B , panels 2 and 4) to the data in Figure 3A (panels 2 and 3 versus 4) and (b): labeled profiles in Figure 3C (panels 2 and 4) to the unlabeled data in Figure 1S (black bars).
Moreover, immunodetectable incorporation of [ 33 P]-orthophosphate into UGTs and PKCε confirmed both proteins are phosphorylated in parallel and that curcumin downregulates the incorporation with eventual recovery without affecting specific protein, again suggesting PKCs support phosphorylation of UGT that is most likely regulated via signaling events.
UGT and PKC in the Endoplasnuc
Reticulum -To demonstrate co-localization of PKCε and ERbound UGT1A7His, we first demonstrate the lack of overlapping background immunofluorescence. As Figure 3SB (panels 1, 2 and 4) revealed no background immunofluorescence in nontransfected COS-1 cells with or without considering DAPI fluorescence ( Figure 3SB , panels 3 and 5), we established the fact that UGT1A7 and PKCε co-localize to the ER outside the nucleus. As shown in Figure 3S , we targeted phospho-serine-729-PKCε with rabbit antiphospho-serine-729-PKCε with detection by donkey anti-rabbit FITC conjugate and UGT1A7His with mouse anti-His Tag with detection by donkey anti-mouse TRITC conjugate; assembly of their fluorescent images fused to generate yellow fluorescence, confirming activated PKCε (7) co-localizes with UGT1A7His ( Figure 3SA, panels 1, 2 and 4) outside the nucleus according to DAPI fluorescence ( Figure 3SA, panels 3 and 5) .
Co-localization of PKCα with Calnexin and
Calreticulin-Before continuing with PKC and UGT co-localization studies, we examined whether PKCα co-localizes with ER marker proteins. Although it is well documented that calnexin and calreticulin are ER marker proteins, it is not commonly appreciated that PKC isozymes localize or translocate to the ER membrane in response to appropriate signal(s) according to the Mochley-Rosen model discussed below (33) . To assess co-localization of calnexin or calreticulin and PKCα in nontransfected COS-1 cells, rabbit anti-calnexin and mouse anti-PKCα were added as targets and visualized with donkey anti-rabbit FITC conjugate and donkey antimouse TRITC conjugate, respectively. To examine, separately, for co-localization of calreticulin and PKCα, rabbit anti-calreticulin and mouse anti-PKCα were added as targets and visualized with donkey anti-rabbit FITCconjugate and donkey anti-mouse TRITCconjugate, respectively. Through fusion of immunofluorescent images of calnexin and PKCα ( Figure 4A , panels 1, 2 and 4) and that for calreticulin and PKCα ( Figure 4B , panels 1, 2 and 4), it is evident that both ER markers co-localize with PKCα outside fluorescein-containing nuclei ( Figure 4A /B, panels 4 and 5), which is consistent with our demonstrations that PKC isozymes colocalize with ER bound UGT isozymes.
Co-localization of UGT1A10His and PKCα or δ-
To determine whether other PKC isozymes support UGT1A7 or UGT1A10, we carried out other co-localization studies. As PKCα or PKCδ seldom co-immunoprecipitated with UGT1A7His and PKCε seldom co-immunoprecipitated with UGT1A10 or 1A10His, we examined PKCα or PKCδ co-localization with 1A10 expressed in COS-1 cells. For PKCα and UGT1A10 colocalization, we exposed 1A10-transfected cells to mouse anti-PKCα, which was again visualized with donkey anti-mouse TRITC-conjugate, and to rabbit anti-His, which was visualized with donkey anti-rabbit-FITC conjugate ( Figure 4C, (panels 2  and 1) ; assembly of the fluorescent images led to fusion that generated yellow fluorescence (panel 4) on a frequent basis, indicating the two proteins co-localized outside DAPI-fluorecent nuclei (panel 5 versus 3). For PKCδ and UGT1A10His co-localization, rabbit anti-PKCδ targeted PKCδ, which was visualized with donkey anti-rabbit FITC conjugate ( Figure 4D, panel 1) , and mouse anti-His targeted 1A10His, which was visualized with donkey anti-mouse TRITC conjugate (panel 2); assembly of their fluorescent images generated yellow fluorescence (panel 4), which was evident outside DAPI-fluorescent nuclei (panel 5 versus 3). There was no detectable background cellular immunofluorescence for PKCα and UGT1A10 co-localization or for PKCδ and UGT1A10His co-localization (see Figure 4S , A and B). Thus, co-localization results suggest phosphorylation of UGT1A10 is most likely supported by PKCα and/or δ, and not by PKCε, in COS-1 cells. Consistent with interactions with a different selection of PKCs, UGT1A10 appears in a substantially larger complex than UGT1A7 in preliminary purification studies (Basu, N.K., Banerjee, R., and Owens, I.S. Manuscript in preparation.)
Specificity of the anti-UGT-CE-To verify the specificity of anti-UGT-CE, we compared antiHis immunoprecipates derived from non transfected COS-1 cells versus those from UGT1A7His and 1A10His-transfected COS-1 cells. Results show no detectable signal in nontransfected cells using anti-UGT-CE as shown in Figure 5A , confirming our previous results (7).
Co-immunoprecipitation of PKCε, ε-RACK, and
UGT1A7His from 1A7His-expressing COS-1 Cells -As we have clearly demonstrated that each of three PKC isozymes co-localizes with UGTs, we analyzed for the effect of curcumin and calphostin C on co-immunoprecipitation. Inasmuch as UGT1A7His and phospho-serine-729-PKCε co-localized in 1A7-transfected cells, we attempted to co-immunoprecipitate the two proteins with anti-His from solubilized cellular extracts (described in Methods) to analyze for related proteins by Western blot after resolution in a 10 % SDS-PAGE system. For untreated cells, UGT protein, detected with anti-His and anti-UGT-CE ( Figure 5B, panels 6 and 5, lane 1) , was heavily phosphorylated as detected with antiphospho-serine (panel 4); in addition, PKCε (panel 3) with high phospho-serine content (panel 2) was readily immunodetected using anti-PKCε and anti-phospho-serine-729-PKCε, respectively. We also detected the receptor for activated PKCε (19), ε-RACK (β-COP) (panel 1), the ε-specific receptor that translocates/anchors activated PKCε proximal to its substrate. If one compares effects of curcumin and calphostin-C treatment, 75 μM curcumin caused complete disassociation of β-COP and PKCε and dephosphorylation of UGT1A7 at 30 min with incomplete recovery by 5 hr, whereas 250 nM calphostin-C caused minor effects on these same proteins, but 500 nM completely disassociated PKCε and β-COP and dephosphorylated 1A7. The coordinate loss of PKCε, β-COP and phosphorylation of UGT following curcumin or calphostin-C treatment indicates these factors are likely located in a complex to support UGT1A7 phosphorylation and activity. Consistent with these results, overexpression of PKCε increased UGT1A7 activity expressed in COS-1 cells (7). Interestingly, UGT1A7His requires approximately one-half concentration compared to wild-type UGT1A7; hence, 75 μM curcumin for 1A7His is equivalent to 150 μM for 1A7 to achieve similar inhibitions (see Figure 1A and 1S and Figure 5B ).
Co-immunoprecipitation of PKCα or PKCδ with
UGT1A10His-Consistent with the co-localization results, PKCα or PKCδ is co-immunoprecipitable with UGT1A10His from solubilized cellular extracts when analyzed by Western blot following resolution in a 4→15 % SDS-PAGE system ( Figure 5C ). Whereas analysis with anti-His and anti-UGT-CE showed no effect on UGT1A10 protein level by treatments with 200 and 400 μ M curcumin or 250 and 500 nM calphostin-C, both chemicals caused considerable loss of UGT1A10 phospho-content and of PKCα or PKCδ protein content. By comparison, however, there was far less loss of UGT1A10 phospho-content and of PKCα and PKCδ levels in this study with 200 μM curcumin and 500 nM calphostin C compared to the drastic effect of 75 μM curcumin and 500 nM calphostin-C on UGT1A7 and PKCε (compare to Figure 5B ), indicating 1A10 and PKCα/δ are much more resistant to these agents in COS-1-cell model.
Evidence the Phosphorylation Process of UGTs
Participates in PKC-mediated Signaling -To determine whether UGT phosphorylation is regulated by PKC-dependent signaling, we examined the effects of various PKC agonists and antagonists on UGT activity in curcumininhibited LS180 cells. Addition of phosphatase inhibitor I, calyculin-A (34), at time zero versus its addition 1-hr later ( Figure 6A , arrow) shows calyculin-A protected against curcumin inhibition at both times, but it was most effective when added at time zero, suggesting calyculin-A partially protected by inhibiting phosphatase removal of phosphates group(s). Also, 100 μM sodium orthovanadate showed 35 to 40 % stimulation of constitutive UGT activity (data not shown). Dephostatin revealed minor protection against curcumin inhibition. The response to phosphatase treatment is consistent with phosphorylation that is undergoing regulation due to phosphatase (35) and kinase signaling events.
Our attempts to determine whether the PKC system involving UGT phosphorylation is mediated by the EGF-receptor in colon cells showed a 20% increase in glucuronidating activity with EGF treatment (data not shown). Similarly, curcumin showed a 20% displacement of [ 125 I]-EGF binding to its receptor. It was not possible, therefore, to show a highly significant involvement of EGF in UGT activity in LS180 cells.
Furthermore, we examined whether treatment of LS180 cells with typical PKC agonists, DAG, PMA and PS, could stimulate curcumin-inhibited UGT, which was shown in Figure 3B to be dissociated from PKCε (33) . When 30 μM DAG and curcumin were combined, activity was only reduced 50% in one hr ( Figure  6B ) compared to nearly 100 % with curcumin alone; its addition to inhibited cells (arrow) showed a robust 80 % recovery that gradually reached 100% after 3 hr. Similar treatment of inhibited UGT with PMA (2.0 μM) showed 80 % recovery by 3 hr, while PS initially showed 35 % recovery that increased to 120%. By comparison, curcumin alone showed only 30 % recovery by 3 hr. Phosphorylation of UGTs regulated by PKCmediated signaling is similar to that seen for other cellular processes following treatment with DAG, PMA or PS, which leads to rapid activation with PKC usually undergoing attachment to membranes or other structures (36,37) with increased phosphorylation of substrates.
Effects of PKCε-specific Translocation Agonistand Antagonist-peptides on UGTs in LS180 Cells
-Recently, it was determined that activated PKC isozymes are translocated or compartmentalized proximal to substrate by binding to an isozymespecific receptor for activated C-kinase (RACK) (33, 38, 39) such that substrate specificity is, at least, partially imposed by differential localizations. Exposure of curcumin-inhibited cells to the pseudo ε-RACK peptide agonist that stimulates translocation of PKCε (38) in a concentration-dependent manner culminated in 45 % maximum curcumin-inhibition of UGT after correction for Antennapedia-carrier conjugated control ( Figure 5S ), which was, predictably, due to increased PKCε binding to ε-RACK proximate to UGT with greater phosphorylation and glucuronidating activity (33) . As pseudo ε-RACK and ε-RACK sites of PKCε bind intramolecularly to maintain the inactive state, pseudo ε-RACK peptide competes out binding of pseudo ε-RACK allowing the higher-affinity ε-RACK translocator to displace, subsequently, the pseudo-specific peptide causing partial activation/translocation with PKCε anchorage near its substrate (36) .
Because part of the ε-RACK binding site for translocation of PKCε is within its unique V1 segment (33, 40) , we tested an appropriate peptide sequence from that region on constitutive UGT in LS180 cells. Addition of a translocationinhibitor octapeptide (Oct) caused 50% inhibition of UGT activity at 3 hr compared to an insignificant effect by its scrambled (Scr) control ( Figure 6C ). Previously, we showed that increasing concentrations of the Oct-peptide attached to Antennapedia-carrier (38) caused progressive inhibition culminating at 50 % (without correction for activation) after 3 hr (7) Effect of PKCε-specific siRNA on PKCε and UGT1A7 and its Activity-To gain additional evidence that PKCε supports UGT1A7His activity, we tested the effect of targeted disruption of PKCε-specific mRNA on 1A7His expressed in COS-1 cells 48 hr after treatment using Western blot analysis and in-vitro activity. Results show whereas UGT1A7 protein level was not affected by PKCε-specific siRNA ( Figure 6D, panel 2) , there was a 65 % loss of its activity (panel 4), which is consistent with the nearly complete loss of detectable PKCε protein (panel 1) that predictably supports phosphorylation of UGT1A7 that is required for its activity. P] ATP into nascent UGT1AHis was 2.7-fold higher than in the absence of the kinase ( Figure 6E ). Affinity purification of the newly synthesized UGT1A7His phosphorylated by PKCε confirms UGT1A7 is a substrate (middle panel, lane 3) for this kinase when compared to unlabeled 1A7 in the absence of this isozyme (middle panel, lane 2). A Western blot probed with anti-UGT-CE (bottom panel) shows newly synthesized protein requires both ATP and PKCε for phosphorylation. It is noted that the molecular weight of nascent UGT1A7His is approximately 53 kDa ( Figure 6E , middle and bottom panels) compared to 55 to 58 kDa for in-cellulo synthesized UGT1A7His ( Figure 5A ,B and C).
In vitro Transcription, Translation and Phosphorylation of UGT1A7 by PKCε-
Identification of Possible Constitutive PKC
Activators that Support UGT Activity-Because routine cellular oxidants-also known as reactive oxygen species (ROS)--were suggested to modulate Zn-complexed thiols in the regulatory domain of PKC leading to activation (10, 43) and H 2 O 2 was shown to activate PKC via increased phosphorylation of tyrosine in its catalytic domain (20, 21, 39) , it was of interest to determine if these second messengers affected UGT activity. Since oxidants were used in both studies cited, we examined the effects of catalase and herbimycin-A on constitutive and H 2 O 2 -activated UGT in LS180 cells. Upon establishing optimum levels of catalase and herbimycin-A to downregulate constitutive UGT ( Figure 7A ) and conditions to H 2 0 2 -activate UGT and PKCε maximally ( Figure  7B , lower, bar 5), catalase (50 %) and herbimycin-A (88 %) treatments were shown to inhibit constitutive or H 2 O 2 -activated UGT equally ( Figure 7A , bars 1,3 vs Figure 7B , bars 5,7 and Figure 7A , bars 4,6 vs Figure 7B , bars 5,9). Hence, catalase was far less efficient in removing ROS than herbimycin-A was at inhibiting H 2 O 2 -activated tyrosine phosphorylation of PKCs. Hydrogen-peroxidetreatment enhanced phosphotyrosine-PKCε and phosphoserine-UGT in parallel reaching a maximum simultaneous with that for UGT activity; following maximum H 2 O 2 -activation ( Figure 7B, panels 1 and 3) , catalase-and herbimycin-A-dependent decreases in phosphotyrosine-PKCε and phosphoserine-UGT appeared to parallel decreases in UGT activity ( Figure 7B , bars 5,6,7 and 5, 8, 9) . Also, 50 μM curcumin nearly abolished phosphotyrosine-PKCε and phosphoserine-UGT with nearly complete inhibition of UGT activity ( Figure 7B , panels 1, 3, lane 10 versus bar 10); H 2 O 2 -activation after curcumin treatment enhanced phosphotyrosine-PKCε and phosphoserine-UGT with a modest increase in UGT activity (bar 11), whereas calphostin-C treatment completely abolished phosphorylation of PKCε and UGT with no response to H 2 O 2 -treatment (lanes 12, 13 and bars 12 and 13). These observations suggest ROS-mediated activation of PKC is important in sustaining phosphorylation of UGT by PKCdependent signaling. Further, UGT downregulation by tyrosine kinase-specific inhibitor, herbimycin-A, suggests cellular oxidant-/ H 2 O 2 -activated PKC via tyrosine phosphorylation also plays a role in sustaining UGT activity (20, 21) .
DISCUSSION
Overall, we have provided evidence that UGTs in LS180 cells and the 10 different human isozymes independently expressed in COS-1 cells undergo phosphorylation, which is supported by PKC isozymes based on inhibition of both UGT activity and its phosphorylation by curcumin or calphostin-C. [Our earlier studies uncovered 3-5 predicted PKC phosphorylation sites in each of 10 UGTs examined (5) .] Inhibition was confirmed with 6 different substrate activities tested (4, 6) with extracts of LS180 and transfected COS-1 cells. Mutants at 2 out of 4 sites in recombinant UGT1A1 (5), UGT1A7 (7), and UGT1A10 (6,7) had null activity, and activity for the mutant at the third site showed a marked shift in pH optimum for assay conditions with emergence of new substrate activities (7) . The fourth site is predicted to be exposed to the cytoplasm (44) distal to the active site projecting into the ER lumen. Coimmunoprecipitation of PKCε, PKCα and PKCδ with UGT1A7, UGT1A10 and UGT1A10, respectively, confirmed preferential association of select PKC and UGT isozymes. Our demonstration of greater resistance of UGT1A10 association with PKCα and δ than UGT1A7 to PKCε is consistent with the higher concentration of curcumin and calphostin-C required to inhibit 1A10 than 1A7 activity. The fact that UGT1A10 required 2 to 2.5 times higher concentrations of curcumin and calphostin-C than 1A7 to achieve 95 % inhibition suggests the PKCs and/or UGTs are differentially sensitive to the two reagents. While the PKCε-specific siRNA (45) markedly reduced UGT1A7 activity, in-vitro PKCε-dependent phosphorylation of newly synthesized UGT1A7His confirms that 1A7 serves as a bona fide substrate for the kinase. Thus, we provide strong evidence that at least 3 PKC isozymes are involved in phosphorylation of UGT isozymes. Moreover, our demonstration here that PKCα colocalizes with both ER-marker proteins, calnexin and calreticulin, is independent evidence that PKC isozymes attach to ER, which agrees with a previous demonstration that PKC and calreticulin are associated (46) .
To understand UGT phosphorylation and its linkage to PKC, we examined properties associated with PKC control of cellular events such as proliferation, apoptosis, adhesion, stress and others (36) . PKCε and δ are among the DAG-dependent novel category (δ,ε,η, and θ), and PKCα is among the DAG-and calcium-dependent classical category (α, βI, βII, and γ), indicating both categories are involved in controlling UGT activity in colon and COS-1 cells. In addition, protection against curcumininhibition of UGT phosphorylation by phosphatase inhibitor, calyculin-A, effectively restores PKC phosphorylation, thereby providing evidence that phosphatase(s) participate in regulating UGT phosphorylation and activity. The robust stimulatory effects of typical PKCdependent signaling mediators (37), DAG, PMA and PS, on curcumin-inhibited UGT indicate phosphorylation undergoes regulation via signaling events. Our failure to observe these agonist(s) effects on constitutive UGT activity in control LS180 cells suggests signaling conditions are maximally optimized. Consistent with other PKC-mediated phosphorylation models (33), modulations of UGT activity by antagonist and agonist translocation-specific peptides for PKCε (7, 33, 38, 40, 41) are evidence that UGT phosphorylation supported by PKC is regulated similar to that observed in other cellular models.
To identify constitutive PKC activators that support UGT activity, we considered the potential for routine endogenously generated superoxide anions (20, 21) to activate PKCs by disrupting oxygen-sensitive Zn-complexed thiols in the regulatory domain of PKC (10) and/or by stimulating tyrosine phosphorylation in the catalytic domain, which is sensitive to herbimycin-A (20, 21) (Figure 7 ). Concentrationdependent catalase and herbimycin-A-based decreases in constitutive UGT activity in LS180 cells was essentially duplicated with H 2 O 2 -activated UGT activity. For example, catalase and herbimycin downregulation of UGT was independent of cellular conditions, which suggests constitutive oxidants or ROS may, in fact, act as second messengers to activate PKCs via effects on both the regulatory domain and tyrosine phosphorylation in the catalytic domain to sustain constitutive UGT phosphorylation ( Figure 7B ). Hence, rapid downregulation of constitutive UGT activity by antioxidant, curcumin, is consistent with oxidants or ROS stimulants to sustain activity, as depicted in Figure 8 .
A credible rationale for why UGTs serve as targets for the PKC-mediated signaling pathway may relate to effects that naturally occurring chemicals --some of which are UGT substrates--have on the unique structural features of thiols in PKC regulatory domain (10, 43) . In addition, it is noted that H 2 O 2 -responsive tyrosine phosphorylation sites exist in the catalytic domain (20, 21) and antioxidant-inhibitable thiols exist in the catalytic domain (10, 47) . Oxidation of cysteines in the regulatory region by cellular oxidants releasing autoinhibition with cofactorindependent activation of PKC (10, 20, 21) and inhibition by high levels of oxidized antioxidants acting on critical cysteines in the catalytic domain (10, 43, 47 ) make the isozymes targets (10, 47) . Whereas routine cellular oxidants capable of providing on-going activation of PKCs (21) (22) (23) to support serine/threonine-based phosphorylation of critical constitutive enzymes, UGTs --which have a vast capacity to inactivate agents detrimental to PKCs--could represent the interdependent pressure for the enzymes described in this report. Predictably, a balance in oxidants and antioxidants is critical for the homeostasis of PKC activity, as well as induced and episodic activation of PKCs, to allow optimal regulation of the many cellular functions controlled by this kinase system. Constitutive UGTs have the capacity to glucuronidate diet-derived inhibitory polyphenolic antioxidants (48,) in order to prevent cellular accumulation and reduce the threat to homeostasis of PKC functions. Examples of such antioxidants are curcumin, quercetin and nordihydroguaiaretic acid (4, Figure 1B ).
Whereas it is indicated that cells need and use signal transduction to detect and respond appropriately to a changing environment (49) , finding the active state of UGT isozymes is controlled by signaling events suggests protecting the cell against chemical exposure necessarily represents a changing environment to which the cell must respond with appropriate modifications (49). UGT conversion of a vast number of chemicals to high excretability that is linked to signal-regulated phosphorylation suggests glucuronidation represents an adaptable response that is sustained under many conditions. The role phospho group(s) play in UGT catalysis has not been established. The fact that our earlier report ( Figure 5 in ref. 7) indicated the UGT1A7-S432G mutant at a PKC phosphorylation site or targeted PKCε-specific inhibition of 1A7-expressed in COS-1 cells gained new substrates which signifies phospho-group(s) participate in substrate selection. Based on this result, it is possible that regulated phosphorylation via signaling allows UGT adaptations of differential phosphate utilization in order to convert (inactivate) the numerous chemical structures that an isozyme handles.
Moreover, this is the first demonstration, to our knowledge, that PKC mediates regulated phosphorylation of ER-bound drug metabolizing enzymes.
The dual capacities of chemopreventive agents to be beneficial antioxidants and, at the same time, serve as UGT substrates are possible (Figure 8 ). Beneficial antioxidant effects are reported to occur at relatively low concentrations, ranging from 1.0 to 10.0 μM, for many chemopreventive polyphenols (28, 50) . By comparison, efficient metabolism of exogenous chemicals by UGTs, which generally have Km values greater than 10 μM (4), is predicted to occur at relatively high concentrations. Less than inhibitory levels allow both PKC and UGT activity (28) , and, by inference, constitutive PKC and UGT activities appear interdependent, which could be critical for proper PKC-mediated signaling.
A complete understanding of the dependence of UGT activity on PKC under various cellular conditions should become clearer in the future. Finding this primary detoxification system, which is also GI-distributed (4), is subject to rapid downregulation by dietary and other antioxidants demonstrates the presence of an unsuspecting risk of facilitated absorption of toxins and/or therapeutic drug levels due to rapid downregulation of UGT isozymes. Importantly, the dramatic and transitory down regulation of UGT by agents that target PKC has significant in-vivo implications for establishing models for blocking glucuronidation so as to greatly improve absorption and therapeutic efficacy of glucuronidatable drugs (51) and to make appropriate determinations about chemical toxicities, therapeutic drug administrations and other PKC-dependent cellular events.
or 500 nM calphostin-C as shown, were harvested; cell extracts were assayed in-vitro as described in Methods. Experiments, carried out as described in Methods, were repeated thrice in triplicates; standard errors ranged from ±2 to ±5 %. The MTT assay did not show toxicity after 8 hr. B) In-vitro glucuronidation of curcumin by UGT1A7-and UGT1A10-expressed in COS-1 cells used increasing concentrations. Experiments, carried out as described in Methods, were repeated thrice in triplicates; standard errors ranged from ±2 to ±3 %. . A) Specificity of Anti-UGT-CE. Non-transfected and UGT1A7His-and 1A10-Histransfected COS-1 cells were processed for immunoprecipitation with anti-His as described under Methods. Western blots prepared after resolution of samples in a 4-15 % SDS-PAGE system as described under Method were probed with anti-UGT-CE. B) Co-immunoprecipitation of PKCε and UGT1A7His expressed in COS-1 cells. Upon terminating the experiment in which UGT1A7His-transfected COS-1 cells had been treated or untreated with 75 μM curcumin (as shown above) or calphostin-C for 1 hr, 60,000-g supernatants generated as described under Methods were immunocomplexed with anti-His, trapped with protein A-Sepharose for resolution in a SDS-10 % PAGE system and transblotted onto nitrocellulose membrane. Proteins migrated as follows: β-COP, 110 kDa; PKCε, 96 kDa; and UGT1A7His, 58 kDa. The membrane was probed according to Methods with different primary antibodies as follows: β-COP (ε-RACK), phosphoserine-PKCε, PKCε, phosphoserine, UGT-CE and His. C) Co-immunoprecipitation of UGT1A10His, PKCα and PKCδ. Co-immunoprecipitation of PKCα and PKCδ expressed in UGT1A10-transfeceted COS-1 cells, which had been treated 1 hr each with curcumn or calphostin-C as shown, was carried out with 60,000-g supernatants as described in Figure 5B Legend. Supernatants were immunocomplexed with anti-His, trapped with protein A-Sepharose for resolution in a 4 →15 % SDS-PAGE system and transblotted onto nitrocellulose membrane. Figure 6 . A) Effect of calyculin-A on curcumin-inhibited UGT activity in LS180 cells. Calyculin-A (6 nM) was added with or without curcumin or 1 hr after curcumin (50 μM); its effect on control or inhibited cells was assessed as shown. [Calyculin-A is a protein phosphatase 1 inhibitor.] Standard errors for UGT activity range between ± 1 and ±4 % in 3 experiments performed in triplicates. B) Effects of PKC agonists on curcumin (50 μM)-inhibited UGT were examined with either 30 μM DAG, 2.0 μM PMA, or 100 μg/mL PS as shown. Control activity was 1817±88 pmol/mg prot./hr. Standard errors for UGT activity range between ± 2 and ± 5 % in 3 separate experiments. C) Effect of PKCε-specific translocationinhibitor on UGT activity. Non-conjugated 8-amino acid peptide (Oct) (175 μM) or its scrambled (Scr) was introduced into saponin permeabilized (18) LS180 cells as described in Methods. Also, the rationale for PKC isozyme-specific inhibition is described under Methods and/or Results. Control activity was 1952±102 pmol/mg prot./hr. UGT assays in panels A-D used capsaicin and eugenol (not shown). * indicates p ≤ 0.01; ** indicates p ≤ 0.001. D) Effect of silencing PKCε on UGT1A7 activity. siRNA specific for PKCε (100 nM) or control siRNA (100 nM) was transfected into COS-1 cells following expression of UGT1A7 for 24 hr; incubation continued for 48 hr before harvesting cells for glucuronidation of eugenol or mycophenolic acid (shown, see ref. 51) in a 2-hr incubation. For Western blot analysis, samples were solubilized, fractionated by centrifugation as previously described (7), 60,000-g supernatants were resolved in a 4→15 % SDS-PAGE system and transblotted. For Western analysis, anti-PKCε, anti-UGT-CE and anti-β-actin were used as previously described (7). * indicates p ≤ 0.01; ** indicates p ≤ 0.001. E) In-vitro transcription, translation and phosphorylation of UGT1A7His by PKCε. pcDNA3.1-UGT1A7His construct was linearized and transcribed for synthesis of nascent protein to undergo in-vitro PKCε-dependent phosphorylation using [γ 33 P] ATP with as described under Methods; accordingly aliquots of the kinased samples were counted. Affinity purified control and experimental samples of [ 33 P]-UGTHis were analyzed in duplicate gels; one was dried for autoradiography and one was used for Western blot with anti-UGT-CE as described under Methods. Samples are defined at the bottom of Figure 6E . ** indicates p ≤ 0.001. Proposed model for effects of agonists and antagonists on PKC activity that controls UGT activity. The PKC cartoon illustrates 2 modes of regulation: 1) well-established upstream phosphoinositide-dependent kinase-1 (PDK-1) and tyrosine kinase(s) phosphorylate conserved serine/threonine and tyrosines (20, 21, 36, 39) , respectively, in the catalytic domain generating putative competent and active PKC, and 2) the allosterically long-term mediator (PMA) or lipid-derived shortterm agonists, DAG and phosphatidylserine (PS)] (Figure 6B ), activate competent PKC via the regulatory domain (36) triggering attachment to specific cellular structures. Although the cartoon suggests direct phosphorylation of ER-bound UGT by PKC based on parallel curcumin/calphostin-C inhibition of phospho-serine/radiolabeling with [ 33 P]orthophosphate and UGT activity ( Figures 3A, B and C) , the fact that UGT1A7 acquired new substrate activity due to loss of serine-432 phosphorylation by PKCε-translocation-inhibitor peptide strongly suggests PKCε directly phosphorylates UGT1A7 (7). Curcumin or calphostin-C inhibits attachment of PKC to molecular structures (7, 33, 36) (Figure 5B and C) . Further, cellular oxidants--ROS--can activate PKC via disruption of oxygen-sensitive Zn-complexed cysteine thiols in the regulatory domain (10,47) and/or via stimulation of tyrosine phosphorylation of PKC ( Figure  7B ). Consistent with PKC activation via H 2 O 2 -stimulated tyrosine phosphorylation, which is inhibited by herbimycin-A (20,21), we observed inhibition of both constitutive and peroxide-stimulated UGT by both agents (Figures 7A,B) . Inasmuch as cellular exposure to high concentrations of oxidized antioxidantssuch as curcumin and nordihydroguaiaretic (4) -can disrupt critical cysteines in the catalytic domain (10, 43, 47) , the inhibitory effects of 50 μM curcumin, but not 25 μM (not shown), on both PKC phosphorylation and UGT activity are consistent with curcumin antioxidant action. Low levels (1.0 to 10 µM) of antioxidant polyphenols can act chemopreventively to scavenge oxidants (52) . Potentially, UGTs with high Km values (≥ 10 µM) (4) and PKC isozymes with differential inhibitory sensitivities (Figure 2) to polyphenols enable the PKC-UGT signaling pathway to adapt to different conditions and remain functional to beneficial chemopreventive action. 
